Cargando…

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes

Regulatory agencies request an assessment of cardiovascular safety for all “new” oral anti-diabetic drugs in order to avoid possible negative effects on cardiovascular events. Dipeptidyl peptidase 4 inhibitors have emerged as a new therapeutic alternative for the treatment of type 2 diabetes mellitu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitale, Cristiana, Rosano, Giuseppe M. C., Prasad, Krishna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818902/ https://www.ncbi.nlm.nih.gov/pubmed/27039303 http://dx.doi.org/10.1186/s12933-016-0379-4

Ejemplares similares

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
por: Evans, Marc, et al.
Publicado: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Open Chromatin State of Dpp4 With Glucocorticoid Treatment—Setting up Shop for Metasteroid Diabetes?
por: Morrow, Nadya M, et al.
Publicado: (2021)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
por: Darsalia, Vladimer, et al.
Publicado: (2018)

COVID-19 and diabetes: Can DPP4 inhibition play a role?
por: Iacobellis, Gianluca
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?
por: Shannon, Richard P.
Publicado: (2013)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Neuroprotective properties of DPP‐4i: A therapeutic target for dementia prevention in elderly diabetic patients?
por: Umemura, Toshitaka, et al.
Publicado: (2023)

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2011)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
por: Choe, Eun Yeong, et al.
Publicado: (2014)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

Streamlined manuscript submission guidelines: Beyond overdue
por: Sobani, Zain A., et al.
Publicado: (2017)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Wang, Qixian, et al.
Publicado: (2018)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Reimbursement Policies for Diabetes Prevention Program (DPP): Implications for Racial and Ethnic Health Disparities
por: Formagini, Taynara, et al.
Publicado: (2021)

Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
por: Farr, Amanda M., et al.
Publicado: (2016)

The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
por: Makrilakis, Konstantinos
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
por: Ahrén, Bo
Publicado: (2008)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
por: Schweizer, Anja, et al.
Publicado: (2013)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
por: Nag, Snehasish, et al.
Publicado: (2023)

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2016)

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?
por: Erol, Rumeysa Selvinaz, et al.
Publicado: (2022)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
por: Mikhail, Nasser
Publicado: (2008)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
por: Yu, Dong-Ni, et al.
Publicado: (2020)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5d6gv0esn02r9tfo1decsqdb4r